121 related articles for article (PubMed ID: 36023821)
1. Arsenic Internally and Subcutaneously in the Treatment of Lymphoma.
South Med Rec; 1882 Nov; 12(11):419. PubMed ID: 36023821
[No Abstract] [Full Text] [Related]
2. Effects of arsenic-azoproteins on mouse lymphoma cells in vivo; with observations on the effects of other anti-lymphoma agents, and on the susceptibility to these effects of lymphoma cells of various types.
KIDD JG
J Exp Med; 1958 Nov; 108(5):665-84. PubMed ID: 13587850
[TBL] [Abstract][Full Text] [Related]
3. THE ANTICOAGULANT AND ANTILYMPHOMA PROPERTIES OF ARSENIC AZOPROTEINS : II. COMBINATION OF ARSENIC AZOPROTEINS WITH FIBRINOGEN AND POLYMERIZING FIBRIN IN VITRO: ALTERATIONS IN MITOSIS OF LYMPHOMA 6C3HED CELLS INDUCED IN VIVO WITH ARSENIC AZOPROTEINS: DISCUSSION OF MEANS WHEREBY ARSENIC AZOPROTEINS MAY ACT UPON LYMPHOMA 6C3HED CELLS IN VIVO.
Broome JD; Kidd JG
J Exp Med; 1964 Sep; 120(3):467-90. PubMed ID: 19867292
[TBL] [Abstract][Full Text] [Related]
4. [Radioactive arsenic in treatment of Hodgkin's disease and mycosis fungoides].
MALLET L; MARCHAL G; DUHAMEL G
Acta Haematol; 1952 Jan; 7(1):27-38. PubMed ID: 14902321
[No Abstract] [Full Text] [Related]
5. [Use of arsenic 76, the radioactive isotope, in the treatment of certain malignant skin diseases].
MALLET L
J Radiol Electrol Arch Electr Medicale; 1951; 32(5-6):506-7. PubMed ID: 14889478
[No Abstract] [Full Text] [Related]
6. [Generalized lymphoblastic sarcoma during severe occupational poisoning by arsenic].
ARNAUD G; BOUCHER H; LIAUME P
Arch Mal Prof; 1951; 12(1):46-8. PubMed ID: 14820450
[No Abstract] [Full Text] [Related]
7. [Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma--review].
Li LH; Li HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1335-9. PubMed ID: 18088496
[TBL] [Abstract][Full Text] [Related]
8. Exposure to non-arsenic pesticides is associated with lymphoma among farmers in Spain.
van Balen E; Font R; Cavallé N; Font L; Garcia-Villanueva M; Benavente Y; Brennan P; de Sanjose S
Occup Environ Med; 2006 Oct; 63(10):663-8. PubMed ID: 16757510
[TBL] [Abstract][Full Text] [Related]
9. Tissue distribution of arsenic after subcutaneous implantation of arsenic trioxide pellet in rats.
ASO T; Abiko Y
J Toxicol Sci; 1978 May; 3(2):109-15. PubMed ID: 755105
[TBL] [Abstract][Full Text] [Related]
10. [Value of arsenic therapy in mycosis fungoides].
HEITE HJ
Arch Dermatol Syph; 1951; 193(2):150-60. PubMed ID: 14924571
[No Abstract] [Full Text] [Related]
11. [Radioactive arsenic in the treatment of Hodgkin's disease and of mycosis fungoides].
MARCHAL G; MALLET L; DUHAMEL G
Bull Mem Soc Med Hop Paris; 1951 Nov 23-30; 67(31-32):1354-8. PubMed ID: 14925908
[No Abstract] [Full Text] [Related]
12. Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay.
Soriano C; Creus A; Marcos R
Mutat Res; 2008 Nov; 646(1-2):1-7. PubMed ID: 18822301
[TBL] [Abstract][Full Text] [Related]
13. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
14. Gene-mutation induction by arsenic compounds in the mouse lymphoma assay.
Soriano C; Creus A; Marcos R
Mutat Res; 2007 Dec; 634(1-2):40-50. PubMed ID: 17851118
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
Yue LM; Chau D; Kwong YL; Tse E
Br J Haematol; 2021 Sep; 194(6):1085-1090. PubMed ID: 34121173
[No Abstract] [Full Text] [Related]
16. Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
Giri U; Terry NH; Kala SV; Lieberman MW; Story MD
Cancer Chemother Pharmacol; 2005 Jun; 55(6):511-21. PubMed ID: 15761769
[TBL] [Abstract][Full Text] [Related]
17. Relative genotoxic potency of arsenic and its methylated metabolites.
Moore MM; Harrington-Brock K; Doerr CL
Mutat Res; 1997 Jun; 386(3):279-90. PubMed ID: 9219565
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
Kchour G; Tarhini M; Kooshyar MM; El Hajj H; Wattel E; Mahmoudi M; Hatoum H; Rahimi H; Maleki M; Rafatpanah H; Rezaee SA; Yazdi MT; Shirdel A; de Thé H; Hermine O; Farid R; Bazarbachi A
Blood; 2009 Jun; 113(26):6528-32. PubMed ID: 19411628
[TBL] [Abstract][Full Text] [Related]
19. Interlaboratory evaluation of the assessment of arsenic bioaccumulation from field collected sediments using Hexagenia spp.
Watson-Leung T; Oke M; McElroy M; Stuart M; Rendas M; Raby M; Mahon K
Environ Toxicol Chem; 2016 Oct; 35(10):2448-2455. PubMed ID: 27271297
[TBL] [Abstract][Full Text] [Related]
20. Novel pathway for arsenic detoxification in the legume symbiont Sinorhizobium meliloti.
Yang HC; Cheng J; Finan TM; Rosen BP; Bhattacharjee H
J Bacteriol; 2005 Oct; 187(20):6991-7. PubMed ID: 16199569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
